Teleflex™
Empowering the future of healthcare

Freesolve™

Resorbable Magnesium Scaffold (RMS)

Metallic performance[1-3]. Fully resorbable[a,4].



Freesolve™ RMS

Delivers like a DES[5]



Proven Orsiro™ Mission™ DES delivery system[6]

Push[5]





Track[5]



Better than contemporary DES[5]

Pre-clinical data

Optimal vessel support[10,11]

Predictable, homogenous resorption process[10]

BIOmag™ backbone
A strong Magnesium alloy[6]

BIOlute™ coating

BIOmag™ core
A strong[6], uniform shape[10]

Histology cut at 90 days after implantation[10]



Equal resorption between struts[10]



Uniform shape due to homogenous strut resorption[10]

More than 3 months vessel support[10,11]

Pre-clinical data at 3 months



Pre-clinical data at 4 months





Clinical data

Magnesium fully resorbed after 12 months[12]

>99%
of struts no longer visible at 12 months[12]

	Angiographic Analysis[c,d]	OCT Analysis[c,d]	
Pre-procedure			*Initial diagnostic*
Post Implantation			*Immediately after implantation, struts are well apposed to the vessel wall.*
6-month follow-up			*While the Magnesium resorption process continues, endothelialization progresses.*
12-month follow-up			*The Magnesium resorption is completed. No struts appear in OCT.*

Clinical data

Excellent safety and efficacy[2,3]

BIOMAG™-I First-In-Human (FIH) trial[3]

In-Scaffold Late Lumen Loss (LLL) in comparison to predecessor study at 12 months



– BIOMAG™-I trial with Freesolve™ RMS 0.24±0.36 mm (95 % CI: 0.17;0.31)*
– BIOSOLVE-II trial with Magmaris™ RMS 0.39 +0.27 mm (95 % CI: 0.31;0.48)*,[8]

The in-scaffold Late Lumen Loss (LLL) for Freesolve™[3] RMS is on the level of a contemporary DES.[7]

Freesolve™ RMS Median LLL: 0.19 mm[3]
Contemp. DES Median LLL: 0.18 mm[7]

Excellent safety and efficacy profile up to 36 months[9]



0.0 % Scaffold Thrombosis | **0.0 %** Myocardial Infarction | **0.0 %** Cardiac Death

Benefits of implant free

The favorable 3-year outcomes support renewed interest in bioresorbable scaffolds as a viable therapeutic option that combines temporary mechanical support with excellent long-term safety and efficacy.[9]

Resorb
By degrading after fulfilling their scaffolding function, they offer all options of future therapies.

Freesolve™ RMS

Vascular Intervention
Coronary

Indicated for de novo coronary artery lesions.[e]

Technical Data

SCAFFOLD	
Scaffold material	Proprietary **BIOmag**™ Magnesium alloy
Strut thickness	ø 2.5 mm: 99 µm; ø 3.0/3.5 mm: 117 µm; ø 4.0 mm: 147 µm
Maximum expandable diameter	Nominal diameter +0.6 mm
Markers	One oval Tantalum marker at each end
Drug coating	**BIOlute**™ resorbable Poly-L-Lactide (PLLA) eluting a limus drug

DELIVERY SYSTEM	
Catheter type	Rapid exchange
Catheter length	140 cm
Recommended guide catheter	6F
Crossing profile	ø 2.5 mm≤1.3 mm; ø 3.0–4.0 mm≤1.4 mm
Guide wire diameter	0.014”
Nominal Pressure (NP)	10 atm
Rated Burst Pressure (RBP)	16 atm

Vessel Sizing

SCAFFOLD Ø (SD)	RECOMMENDED Ø (RVD)
2.50 mm	2.50–2.70 mm
3.00 mm	2.70–3.20 mm
3.50 mm	3.20–3.70 mm
4.00 mm	3.70–4.20 mm

Compliance Chart

	BALLOON DIAMETER (MM)			
	ø 2.50	**ø 3.00**	**ø 3.50**	**ø 4.00**
Nominal Pressure (NP)	10 atm	10 atm	10 atm	10 atm
	ø 2.52 mm	ø 3.04 mm	ø 3.54 mm	ø 4.02 mm
Rated Burst Pressure (RBP)	16 atm	16 atm	16 atm	16 atm
	ø 2.72 mm	ø 3.29 mm	ø 3.79 mm	ø 4.35 mm

1 atm = 1.013 bar

Ordering Information

SCAFFOLD Ø	SCAFFOLD LENGTH				
	13 mm	**18 mm**	**22 mm**	**26 mm**	**30 mm**
2.50 mm	443103	443104	443105	–	–
3.00 mm	443108	443109	443110	482156	443111
3.50 mm	443113	443114	443115	482157	443116
4.00 mm	443118	443119	443120	482158	443121

References
1 Benchtest data, data on file.
2 Haude, M. et al., the Lancet eClinicalMedicine 2023;59: 101940.
3 Haude, M. et al., EuroIntervention 2023;19:1-1 published online May 2023.
4 Seguchi, M. et al., OCT-Analysis 12M, presented at ESC 2023.
5 Data on file, Benchtest data: Freesolve in comparison to Orsiro Mission and Xience Sierra.
6 Data on file.
7 Byrne, RA. et al., Eur Heart J 2015;36:2608-2620.
8 Haude, M. et al., Eur Heart J. 2016;37:2701-9.
9 Haude et Al. Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I study. EuroIntervention 2025;21:e1-e3.
10 Based on pre-clinical data, Seguchi, M. et al., EuroIntervention 2023;18-online publish-ahead-of-print January 2023.
11 Data on file, in comparison to predecessor device.
12 Based on intravascular OCT analysis of the BIOMAG-I trial presented by Dr. M. Seguchi at ESC 2023.

Target Lesion Failure (TLF) is a composite of Target-Vessel Myocardial Infarction (TV-MI), clinically-driven Target Lesion Revascularization (CD-TLR) and Cardiac Death.

*based on QCA paired data [a]99.3% resorbed at 12 months (markers are not resorbable), based on clinical data [b]Xience Sierra DES (Abbott); [c]Angiographic and OCT Analyses derived from two different BIOMAG-I cases, courtesy of Prof. Michael Haude, Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Neuss, Germany [d]The 4P protocol was respected [e]Indications as per IFU.

Refer to IFU

Refer to QR code for a copy of the Instructions for Use for a complete listing of the indications, contraindications, warnings and precautions.

About Teleflex

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

Corporate Office

Phone +1 610 225 6800, 550 E. Swedesford Road, Suite 400, Wayne, PA 19087, USA

Regional Offices

United States: Phone +1 919 544 8000, Toll Free 866 246 6990, cs@teleflex.com, 3015 Carrington Mill Boulevard, Morrisville, NC 27560, USA

Latin America: Phone +1 919 433 4999, la.cs@teleflex.com, 3015 Carrington Mill Boulevard, Morrisville, NC 27560, USA

International: Phone +353 (0)9 06 46 08 00, orders.intl@teleflex.com, Teleflex Medical Europe Ltd., IDA Business and Technology Park, Dublin Road, Athlone, Co Westmeath, Ireland

BIOSOLVE-II and BIOMAG-I based on Kaplan-Meier failure estimate analysis.

472231-EN · REV D · 09 25 PDF

Teleflex™
Empowering the future of healthcare